Praxis Dr. med. Erik-C. Miller
Home
Praxis
Themen
Anti-Ageing
Diabetes
Hormone
Osteoporose
Impfungen
Reisemedizin
Infektionen
Kosmetische
Operationen
Schwanger-
schaft
Verhütung
Vorsorge
Aktuell
Presse
Fragen
Impressum
Literaturquellen
für die zitierten Studien
für die zitierten Studien
In den großen Bibliotheken können diese Arbeiten entweder kostenlos (für Wissenschaftler und Mediziner) oder gegen geringe Gebühr im Original eingesehen werden; die Arbeiten können auch (kostenpflichtig für Alle) als Kopie angefordert werden.
HET und Brustkrebs:
1. Bush, T. L., Whiteman, M. und Flaws, J. A.:
Hormone replacement therapy and breast cancer: a qualitative review.
Obstet. Gynecol. 98 (2001) 498 - 508
2. Chen, C. L.,Weiss, N. S., Newcomb, P., Barlow, W. und White, E.:
Hormone replacement therapy in relation to breast cancer.
J. Am. Med. Ass. 287 (2002) 734 - 741
3. Dailing, J. R., Malone, K. E., Doody, D. R., et. al.:
Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.
Cancer 58 (1988) 163 - 170
4. Kirsh, V. und Kreiger, N.:
Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada.
Cancer Causes Control 13 (2002) 583 - 590
5. Magnusson, C., Baron, J. A., Correia, N., et. al.:
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.
Int. J. Cancer 81 (1999) 339 - 344
6. Mattisson, Irene et. al.: Br. J. Cancer 90 (2004) 122 - 127
7. McGrath, K: New Scientist 181 (2004) 11
8. Persson, I., Yuen, J., Bergkvist, I. und Schaier, C.:
Cancer incidence and mortality in Women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort.
Int. J. Cancer 67 (1996) 327 - 332
9. Porch, J. V., Lee, I. M. und Cook, N. R.:
Estrogen-progestin replacement therapy and breast cancer risk: the Women' Health Study (United States).
Cancer Causes Control 13 (2002) 847 - 854
10. Ross, R. K., Pagnini-Hill, A., Wan, P. C. und Pike, M. C.:
Effect of hormone replacement therapy on breast cancer risk: etrogen versus estrogen plus progestin.
J. Natl. Cancer Inst. 92 (2000) 328 - 332
11. Schairer, C., Lubin, J., Troisi, R., et. al.:
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
JAMA 283 (2000) 485 - 491
12. Weiss, L. K., Burkman, R. T., Cushing-Haugen, K. L., et. al.:
Hormone replacement therapy regimens and breast cancer risk.
Obstet. Gynecol. 100 (2002) 1148 - 1158
HET und KHK (Herz- und Kreislauferkrankungen):
1. Barrett-Connor, E. und Grady, D.:
Hormone replacement therapy, heart disease, and other other considerations.
Annu. Rev. Public Health 19 (1998) 55 - 72
2. Grodstein, F., Stampfer, M. J., Falkeborn, M., Naessen, T. und Persson, I.:
Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish woman.
Epidemiology 10 (1999) 476 - 480
3. Grodstein, F., Manson, J. E., Colditz, G. A., Willett, W. C., Speizer, F. E. und Stampfer, M. J.:
A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
Ann. Intern. Med. 133 (2000) 933 - 941
4. Heckbert, S. R., Kaplan, R. C., Weiss, N. S., et. al.:
Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy.
Arch. Intern. Med. 161 (2001) 1709 - 1713
5. Herrington, D. M., Vittinghoff, E., Lin, F., et. al.:
HERS Study Group: Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).
Circulation 105 (2002) 2962 - 2967
6. Hodis, H. N., Mack, W. J., Lobo, R. A., et. al.:
Estrogen in the prevention of atherosclerosis. A randomized, duble-blind, placebo-controlled trial.
Ann. Intern. Med. 135 (2001) 939 - 953
7. Varas-Lorenzo, C., Garcia-Rodriguez, L. A., Perez-Gutthann, S., et. al.:
Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study.
Circulation 101 (2000) 2572 - 2578
8. Westendorp, I. C., Veld, B. A., Grobbee, D. E., et. al.:
Hormone relacement therapy and peripheral arterial disease. The Rotterdam Study.
Arch. Intern. Med. 160 (2000) 2498 - 2502
9. Writing Group for the Women's Health Initiative Investigators:
Risk and benefits of etrogen plus progestin in healthy postmenopausal woman: principal results From the WHI randomized controlled trial.
JAMA 288 (2002) 321 - 333
We regret that at the moment not yet all left and above in the task bar in English for the order; we operate on it.
Top Next